Artiva Biotherapeutics (ARTV) Consolidated Net Income (2023 - 2026)

Artiva Biotherapeutics (ARTV) has reported Consolidated Net Income for 4 consecutive years, with -$35.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Consolidated Net Income rose 4.46% year-over-year to -$35.2 million; the TTM figure through Mar 2026 stood at -$116.5 million (up 4.44% YoY), while the FY2025 annual figure was -$87.7 million, down 41.86% from the prior year.
• Consolidated Net Income retreated to -$35.2 million in Q1 2026 per ARTV's latest filing, from -$21.2 million in the prior quarter.
• Across five years, Consolidated Net Income topped out at $11.2 million in Q3 2023 and bottomed at -$36.8 million in Q1 2025.
• Historically, Consolidated Net Income has averaged -$22.0 million across 4 years, with a median of -$23.3 million in 2024.
• Annual changes were most pronounced in 2024 — Consolidated Net Income tumbled 400.97% — and 2025, when it soared 30.87%.
• Artiva Biotherapeutics' Consolidated Net Income stood at -$11.6 million in 2023, then tumbled by 100.05% to -$23.2 million in 2024, then gained by 8.73% to -$21.2 million in 2025, then tumbled by 66.17% to -$35.2 million in 2026.
• Business Quant data shows ARTV's Consolidated Net Income at -$35.2 million in Q1 2026, -$21.2 million in Q4 2025, and -$23.4 million in Q3 2025.